Evaluation  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
interindividual  ||| S:18 E:34 ||| JJ
human  ||| S:34 E:40 ||| JJ
variation  ||| S:40 E:50 ||| NN
in  ||| S:50 E:53 ||| IN
bioactivation  ||| S:53 E:67 ||| NN
of  ||| S:67 E:70 ||| IN
methyleugenol  ||| S:70 E:84 ||| NNS
using  ||| S:84 E:90 ||| VBG
physiologically  ||| S:90 E:106 ||| NNS
based  ||| S:106 E:112 ||| VBN
kinetic  ||| S:112 E:120 ||| JJ
modeling  ||| S:120 E:129 ||| NN
and  ||| S:129 E:133 ||| CC
Monte  ||| S:133 E:139 ||| NNP
Carlo  ||| S:139 E:145 ||| NNP
simulations  ||| S:145 E:157 ||| VBD
The  ||| S:157 E:161 ||| DT
present  ||| S:161 E:169 ||| JJ
study  ||| S:169 E:175 ||| NN
aims  ||| S:175 E:180 ||| VBZ
at  ||| S:180 E:183 ||| IN
predicting  ||| S:183 E:194 ||| VBG
the  ||| S:194 E:198 ||| DT
level  ||| S:198 E:204 ||| NN
of  ||| S:204 E:207 ||| IN
formation  ||| S:207 E:217 ||| NN
of  ||| S:217 E:220 ||| IN
the  ||| S:220 E:224 ||| DT
ultimate  ||| S:224 E:233 ||| JJ
carcinogenic  ||| S:233 E:246 ||| JJ
metabolite  ||| S:246 E:257 ||| NN
of  ||| S:257 E:260 ||| IN
methyleugenol ||| S:260 E:273 ||| NN
,  ||| S:273 E:275 ||| ,
1 ||| S:275 E:276 ||| CD
' ||| S:276 E:277 ||| POS
-sulfooxymethyleugenol ||| S:277 E:299 ||| JJ
,  ||| S:299 E:301 ||| ,
in  ||| S:301 E:304 ||| IN
the  ||| S:304 E:308 ||| DT
human  ||| S:308 E:314 ||| JJ
population  ||| S:314 E:325 ||| NN
by  ||| S:325 E:328 ||| IN
taking  ||| S:328 E:335 ||| VBG
variability  ||| S:335 E:347 ||| NN
in  ||| S:347 E:350 ||| IN
key  ||| S:350 E:354 ||| JJ
bioactivation  ||| S:354 E:368 ||| NN
and  ||| S:368 E:372 ||| CC
detoxification  ||| S:372 E:387 ||| JJ
reactions  ||| S:387 E:397 ||| NNS
into  ||| S:397 E:402 ||| IN
account  ||| S:402 E:410 ||| NN
using  ||| S:410 E:416 ||| VBG
Monte  ||| S:416 E:422 ||| NNP
Carlo  ||| S:422 E:428 ||| NNP
simulations ||| S:428 E:439 ||| NNS
.  ||| S:439 E:441 ||| .
Depending  ||| S:441 E:451 ||| VBG
on  ||| S:451 E:454 ||| IN
the  ||| S:454 E:458 ||| DT
metabolic  ||| S:458 E:468 ||| JJ
route ||| S:468 E:473 ||| NN
,  ||| S:473 E:475 ||| ,
variation  ||| S:475 E:485 ||| NN
was  ||| S:485 E:489 ||| VBD
simulated  ||| S:489 E:499 ||| VBN
based  ||| S:499 E:505 ||| VBN
on  ||| S:505 E:508 ||| IN
kinetic  ||| S:508 E:516 ||| NNS
constants  ||| S:516 E:526 ||| VBP
obtained  ||| S:526 E:535 ||| VBN
from  ||| S:535 E:540 ||| IN
incubations  ||| S:540 E:552 ||| NN
with  ||| S:552 E:557 ||| IN
a  ||| S:557 E:559 ||| DT
range  ||| S:559 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
individual  ||| S:568 E:579 ||| JJ
human  ||| S:579 E:585 ||| JJ
liver  ||| S:585 E:591 ||| NN
fractions  ||| S:591 E:601 ||| NNS
or  ||| S:601 E:604 ||| CC
by  ||| S:604 E:607 ||| IN
combining  ||| S:607 E:617 ||| VBG
kinetic  ||| S:617 E:625 ||| NNS
constants  ||| S:625 E:635 ||| VBP
obtained  ||| S:635 E:644 ||| VBN
for  ||| S:644 E:648 ||| IN
specific  ||| S:648 E:657 ||| JJ
isoenzymes  ||| S:657 E:668 ||| NN
with  ||| S:668 E:673 ||| IN
literature  ||| S:673 E:684 ||| NN
reported  ||| S:684 E:693 ||| VBD
human  ||| S:693 E:699 ||| JJ
variation  ||| S:699 E:709 ||| NN
in  ||| S:709 E:712 ||| IN
the  ||| S:712 E:716 ||| DT
activity  ||| S:716 E:725 ||| NN
of  ||| S:725 E:728 ||| IN
these  ||| S:728 E:734 ||| DT
enzymes ||| S:734 E:741 ||| NN
.  ||| S:741 E:743 ||| .
The  ||| S:743 E:747 ||| DT
results  ||| S:747 E:755 ||| NNS
of  ||| S:755 E:758 ||| IN
the  ||| S:758 E:762 ||| DT
study  ||| S:762 E:768 ||| NN
indicate  ||| S:768 E:777 ||| VBP
that  ||| S:777 E:782 ||| DT
formation  ||| S:782 E:792 ||| NN
of  ||| S:792 E:795 ||| IN
1 ||| S:795 E:796 ||| CD
' ||| S:796 E:797 ||| POS
-sulfooxymethyleugenol  ||| S:797 E:820 ||| NN
is  ||| S:820 E:823 ||| VBZ
predominantly  ||| S:823 E:837 ||| RB
affected  ||| S:837 E:846 ||| VBN
by  ||| S:846 E:849 ||| IN
variation  ||| S:849 E:859 ||| NN
in  ||| S:859 E:862 ||| IN
i ||| S:862 E:863 ||| FW
)  ||| S:863 E:865 ||| -RRB-
P450  ||| S:865 E:870 ||| CD
1A2-catalyzed  ||| S:870 E:884 ||| CD
bioactivation  ||| S:884 E:898 ||| NN
of  ||| S:898 E:901 ||| IN
methyleugenol  ||| S:901 E:915 ||| VBG
to  ||| S:915 E:918 ||| TO
1 ||| S:918 E:919 ||| CD
' ||| S:919 E:920 ||| POS
-hydroxymethyleugenol ||| S:920 E:941 ||| JJ
,  ||| S:941 E:943 ||| ,
ii ||| S:943 E:945 ||| CD
)  ||| S:945 E:947 ||| -RRB-
P450  ||| S:947 E:952 ||| CD
2B6-catalyzed  ||| S:952 E:966 ||| CD
epoxidation  ||| S:966 E:978 ||| NN
of  ||| S:978 E:981 ||| IN
methyleugenol ||| S:981 E:994 ||| NN
,  ||| S:994 E:996 ||| ,
iii ||| S:996 E:999 ||| CD
)  ||| S:999 E:1001 ||| -RRB-
the  ||| S:1001 E:1005 ||| DT
apparent  ||| S:1005 E:1014 ||| JJ
kinetic  ||| S:1014 E:1022 ||| JJ
constants  ||| S:1022 E:1032 ||| NN
for  ||| S:1032 E:1036 ||| IN
oxidation  ||| S:1036 E:1046 ||| NN
of  ||| S:1046 E:1049 ||| IN
1 ||| S:1049 E:1050 ||| CD
' ||| S:1050 E:1051 ||| POS
-hydroxymethyleugenol ||| S:1051 E:1072 ||| JJ
,  ||| S:1072 E:1074 ||| ,
and  ||| S:1074 E:1078 ||| CC
iv ||| S:1078 E:1080 ||| CD
)  ||| S:1080 E:1082 ||| -RRB-
the  ||| S:1082 E:1086 ||| DT
apparent  ||| S:1086 E:1095 ||| JJ
kinetic  ||| S:1095 E:1103 ||| JJ
constants  ||| S:1103 E:1113 ||| NN
for  ||| S:1113 E:1117 ||| IN
sulfation  ||| S:1117 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
1 ||| S:1130 E:1131 ||| CD
' ||| S:1131 E:1132 ||| POS
-hydroxymethyleugenol ||| S:1132 E:1153 ||| JJ
.  ||| S:1153 E:1155 ||| .
Based  ||| S:1155 E:1161 ||| VBN
on  ||| S:1161 E:1164 ||| IN
the  ||| S:1164 E:1168 ||| DT
Monte  ||| S:1168 E:1174 ||| NNP
Carlo  ||| S:1174 E:1180 ||| NNP
simulations  ||| S:1180 E:1192 ||| VBD
a  ||| S:1192 E:1194 ||| DT
so-called  ||| S:1194 E:1204 ||| JJ
chemical-specific  ||| S:1204 E:1222 ||| JJ
adjustment  ||| S:1222 E:1233 ||| NN
factor  ||| S:1233 E:1240 ||| NN
( ||| S:1240 E:1241 ||| -LRB-
CSAF ||| S:1241 E:1245 ||| NNP
)  ||| S:1245 E:1247 ||| -RRB-
for  ||| S:1247 E:1251 ||| IN
intraspecies  ||| S:1251 E:1264 ||| JJ
variation  ||| S:1264 E:1274 ||| NN
could  ||| S:1274 E:1280 ||| MD
be  ||| S:1280 E:1283 ||| VB
derived  ||| S:1283 E:1291 ||| VBN
by  ||| S:1291 E:1294 ||| IN
dividing  ||| S:1294 E:1303 ||| VBG
different  ||| S:1303 E:1313 ||| JJ
percentiles  ||| S:1313 E:1325 ||| NN
by  ||| S:1325 E:1328 ||| IN
the  ||| S:1328 E:1332 ||| DT
50th  ||| S:1332 E:1337 ||| JJ
percentile  ||| S:1337 E:1348 ||| NN
of  ||| S:1348 E:1351 ||| IN
the  ||| S:1351 E:1355 ||| DT
predicted  ||| S:1355 E:1365 ||| JJ
population  ||| S:1365 E:1376 ||| NN
distribution  ||| S:1376 E:1389 ||| NN
for  ||| S:1389 E:1393 ||| IN
1 ||| S:1393 E:1394 ||| CD
' ||| S:1394 E:1395 ||| POS
-sulfooxymethyleugenol  ||| S:1395 E:1418 ||| JJ
formation ||| S:1418 E:1427 ||| NN
.  ||| S:1427 E:1429 ||| .
The  ||| S:1429 E:1433 ||| DT
obtained  ||| S:1433 E:1442 ||| VBN
CSAF  ||| S:1442 E:1447 ||| NNP
value  ||| S:1447 E:1453 ||| NN
at  ||| S:1453 E:1456 ||| IN
the  ||| S:1456 E:1460 ||| DT
90th  ||| S:1460 E:1465 ||| CD
percentile  ||| S:1465 E:1476 ||| NNS
was  ||| S:1476 E:1480 ||| VBD
3.2 ||| S:1480 E:1483 ||| CD
,  ||| S:1483 E:1485 ||| ,
indicating  ||| S:1485 E:1496 ||| VBG
that  ||| S:1496 E:1501 ||| IN
the  ||| S:1501 E:1505 ||| DT
default  ||| S:1505 E:1513 ||| NN
uncertainty  ||| S:1513 E:1525 ||| NN
factor  ||| S:1525 E:1532 ||| NN
of  ||| S:1532 E:1535 ||| IN
3.16  ||| S:1535 E:1540 ||| CD
for  ||| S:1540 E:1544 ||| IN
human  ||| S:1544 E:1550 ||| JJ
variability  ||| S:1550 E:1562 ||| NN
in  ||| S:1562 E:1565 ||| IN
kinetics  ||| S:1565 E:1574 ||| NNS
may  ||| S:1574 E:1578 ||| MD
adequately  ||| S:1578 E:1589 ||| RB
cover  ||| S:1589 E:1595 ||| VB
the  ||| S:1595 E:1599 ||| DT
variation  ||| S:1599 E:1609 ||| NN
within  ||| S:1609 E:1616 ||| IN
90 ||| S:1616 E:1618 ||| CD
%  ||| S:1618 E:1620 ||| NN
of  ||| S:1620 E:1623 ||| IN
the  ||| S:1623 E:1627 ||| DT
population ||| S:1627 E:1637 ||| NN
.  ||| S:1637 E:1639 ||| .
Covering  ||| S:1639 E:1648 ||| VBG
99 ||| S:1648 E:1650 ||| CD
%  ||| S:1650 E:1652 ||| NN
of  ||| S:1652 E:1655 ||| IN
the  ||| S:1655 E:1659 ||| DT
population  ||| S:1659 E:1670 ||| NN
requires  ||| S:1670 E:1679 ||| VBZ
a  ||| S:1679 E:1681 ||| DT
larger  ||| S:1681 E:1688 ||| JJR
uncertainty  ||| S:1688 E:1700 ||| NN
factor  ||| S:1700 E:1707 ||| NN
of  ||| S:1707 E:1710 ||| IN
6.4 ||| S:1710 E:1713 ||| CD
.  ||| S:1713 E:1715 ||| .
In  ||| S:1715 E:1718 ||| IN
conclusion ||| S:1718 E:1728 ||| NN
,  ||| S:1728 E:1730 ||| ,
the  ||| S:1730 E:1734 ||| DT
results  ||| S:1734 E:1742 ||| NNS
showed  ||| S:1742 E:1749 ||| VBD
that  ||| S:1749 E:1754 ||| DT
adequate  ||| S:1754 E:1763 ||| JJ
predictions  ||| S:1763 E:1775 ||| NNS
on  ||| S:1775 E:1778 ||| IN
interindividual  ||| S:1778 E:1794 ||| JJ
human  ||| S:1794 E:1800 ||| JJ
variation  ||| S:1800 E:1810 ||| NN
can  ||| S:1810 E:1814 ||| MD
be  ||| S:1814 E:1817 ||| VB
made  ||| S:1817 E:1822 ||| VBN
with  ||| S:1822 E:1827 ||| IN
Monte  ||| S:1827 E:1833 ||| NNP
Carlo-based  ||| S:1833 E:1845 ||| NNP
PBK  ||| S:1845 E:1849 ||| NNP
modeling ||| S:1849 E:1857 ||| NN
.  ||| S:1857 E:1859 ||| .
For  ||| S:1859 E:1863 ||| IN
methyleugenol  ||| S:1863 E:1877 ||| VBG
this  ||| S:1877 E:1882 ||| DT
variation  ||| S:1882 E:1892 ||| NN
was  ||| S:1892 E:1896 ||| VBD
observed  ||| S:1896 E:1905 ||| VBN
to  ||| S:1905 E:1908 ||| TO
be  ||| S:1908 E:1911 ||| VB
in  ||| S:1911 E:1914 ||| IN
line  ||| S:1914 E:1919 ||| NN
with  ||| S:1919 E:1924 ||| IN
the  ||| S:1924 E:1928 ||| DT
default  ||| S:1928 E:1936 ||| NN
variation  ||| S:1936 E:1946 ||| NN
generally  ||| S:1946 E:1956 ||| RB
assumed  ||| S:1956 E:1964 ||| VBN
in  ||| S:1964 E:1967 ||| IN
risk  ||| S:1967 E:1972 ||| NN
assessment ||| S:1972 E:1982 ||| NN
.  ||| S:1982 E:1984 ||| .
